Is Rucaparib on the market?

Rucaparib (Rucaparib) was approved byU.S. Food and Drug Administration (FDA) in April 2015 Breakthrough Therapy Certification, and accelerated approval for marketing in December 2016. The drug was subsequently approved by the European Commission in May 2018. It is currently used to treat recurrent ovarian and prostate cancer in adults and is sold under the trade name Rubraca.

Rucapanib is an anticancer drug that is a member of the poly(ADP-ribose) polymerase (PARP) inhibitors. PARP is an enzyme that plays an important role in DNA repair. Rucaparib is thought to act in several PARP-dependent and PARP-independent mechanisms of action; however, it produces a unique synthetic lethal effect. By targeting genetically mutated cancer cells that lack DNA repair machinery, rucapanib causes cancer cell death and reduces tumor growth. Rucaparib has been shown to delay progression or recurrence of the disease in patients whose cancer has been partially or completely cleared after treatment with platinum-based drugs. This benefit was seen in patients with and without BRCA mutations. Regarding safety, side effects occur frequently but are generally not serious and can be controlled with appropriate treatment.

The original drug Rucapani has not yet been marketed in the country, so it has not entered the medical insurance coverage standards. The European version of rucapani original drug, specifications300mg*60 tablets sold overseas may cost more than 20,000 yuan per box (the price may fluctuate due to exchange rate effects), which is relatively expensive. There are also cheap generic rucapani drugs available overseas, and their pharmaceutical ingredients are basically the same as those of the original rucapani drug. For example, in India, the price of BDR pharmaceutical specifications of 300mg*60 tablets per box may be more than 6,000 yuan (the price may fluctuate due to exchange rate effects).